SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Martín, J.
Right arrow Articles by Arana, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martín, J.
Right arrow Articles by Arana, G
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

case-report

Adalimumab-induced lupus erythematosus

JM Martín

Department of Dermatology, Hospital Clínico Universitario, Valencia, Spain; Dermatology Unit, Hospital Quirón, Valencia, Spain, jmmart{at}eresmas.com

JM Ricart

Dermatology Unit, Hospital Quirón, Valencia, Spain

J Alcácer

Department of Pathology, Hospital Quirón, Valencia, Spain

N Rausell

Department of Pathology, Hospital Quirón, Valencia, Spain

G Arana

Dermatology Unit, Hospital Quirón, Valencia, Spain

Adalimumab, an anti-tumour necrosis factor agent, especially used in the treatment of rheumatoid arthritis, has a good safety profile. One of the most common side-effects of adalimumab is the development of autoantibodies. Despite the induction of autoantibodies, the clinical presentation of immune-mediated complications upon adalimumab therapy, including a lupus-like syndrome, is very rare. We have recently evaluated a new case of adalimumab-induced lupus erythematosus.

Key Words: adalimumab • drug-induced lupus erythematosus • leflunomide

Lupus, Vol. 17, No. 7, 676-678 (2008)
DOI: 10.1177/0961203307088291
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement